Travere Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $114,449 | $81,732 | $74,787 | $62,898 |
Gross Profit | 98,912 | 77,053 | 72,234 | 61,272 |
EBITDA | -12,755 | -25,528 | -45,430 | -40,820 |
EBIT | -38,330 | -57,523 | -52,059 | |
Net Income | -12,755 | -41,226 | -60,264 | -54,811 |
Net Change In Cash | 114,449 | 81,732 | 74,787 | 62,898 |
Free Cash Flow | 4,748 | -53,978 | -45,281 | -23,768 |
Cash | 75,154 | 61,897 | 58,535 | 36,409 |
Basic Shares | 88,946 | 88,356 | 83,105 | 77,779 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $233,175 | $145,238 | $212,018 | $227,490 |
Gross Profit | 225,431 | 133,788 | 204,426 | 220,706 |
EBITDA | -265,773 | -326,246 | -299,422 | -186,679 |
EBIT | -309,328 | -364,776 | -320,141 | -213,296 |
Net Income | -321,545 | -111,399 | -278,482 | -180,091 |
Net Change In Cash | 233,175 | 145,238 | 212,018 | 227,490 |
Cost of Revenue | -101,271 | 79,268 | ||
Free Cash Flow | -338,687 | -322,280 | -214,848 | -38,943 |
Cash | 58,535 | 58,176 | 61,688 | 165,753 |
Basic Shares | 78,889 | 74,267 | 63,758 | 59,832 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.13 |
2025-03-31 | -$0.19 |
2024-12-31 | -$0.47 |
